Saturday, February 14, 2026 2/14/2026

Advancing a second generation C. difficile vaccine

Award Number: U19AI174994
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/25/2023
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Advancing a second generation C. difficile vaccine - PROJECT SUMMARY (Overall) Our goal in the Oklahoma C. difficile U19 program is to transform a strong research base on enteric bacterial pathogens into a nationally-recognized center of excellence for research on C. difficile. Our research goals, commensurate with RFA-AI-022-001 are to provide basic knowledge that explains why vaccine-induced immunity provides suboptimal protection against C. difficile, to understand the human memory B cell response to the pathogen, and to advance the development and testing of second generation vaccine candidates. To achieve these goals, three independent but complementary Research Projects have been devised which are supported by an Administrative Core that includes bio-statistics support, and a Research Core to allow for integrated and consistent C. difficile challenge experiments within and between the Research Projects. The following Specific Aims will therefore be accomplished: Specific Aim 1: Establish a center of excellence for research on C. difficile. Specific Aim 2: Test a second-generation vaccine candidate that shifts the balance between the pathogen and host resulting in a more efficacious vaccine response and determine how C. difficile toxin B subverts those responses (Project 1). Specific Aim 3: Determine the functional diversity of human TcdB- specific memory B cell-derived antibody (Project 2). Specific Aim 4: Determine the impact of TcdA and TcdB on the enteric nervous system-coordinated humoral response to vaccination and infection (Project 3). These efforts will also be supported by NIH-funded programs at OUHSC that provide vital additional resources. By the end of the first five year funding period we will advance the goal of understanding why vaccine responses to C. difficile are sub-optimal, advance a second generation vaccine, and establish the means for a sustained research program on C. difficile.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,315,168 )
2025	2025	UNIVERSITY OF OKLAHOMA	865 RESEARCH PKWY	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	3	7/18/2025	NON-COMPETING CONTINUATION	$1,315,168
														Subtotal = $1,315,168

Issue Date FY: 2024 ( Subtotal = $1,315,168 )
2024	2024	UNIVERSITY OF OKLAHOMA	865 RESEARCH PKWY	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	2	7/8/2024	NON-COMPETING CONTINUATION	$1,315,168
														Subtotal = $1,315,168

Issue Date FY: 2023 ( Subtotal = $1,315,168 )
2023	2023	UNIVERSITY OF OKLAHOMA	865 RESEARCH PKWY	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	1	7/24/2023	NEW	$1,315,168
														Subtotal = $1,315,168

Grand Total All Awards = $3,945,504

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advancing a second generation C. difficile vaccine

Award Number: U19AI174994

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/25/2023

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer